An additional study by Hu et al discovered that interleukin 17 receptor B (CRL4) was significantly increased in cisplatin‐resistant ovarian cancer cells, and knocking down CRL4 with shRNA reversed cisplatin resistance in ovarian cancer cells. This evidence concerns the gene IL17RB and ovarian carcinoma.